ERS: European Respiratory Society

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient outcomes.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

A Danish cohort study found 100% RSV vaccine effectiveness in COPD, but Jorgen Vestbo, MD, urges caution interpreting real-world results.

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin deficiency.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.

Jorgen Vestbo, MD, discusses new COPERNICOS trial data showing patients who do not meet a specific eosinophil threshold can have inhaled ICS safely reduced.

COPD kills at rates rivaling heart failure and exceeding prostate and breast cancer, per a new study and US mortality data.

Empathy and communication strengthen patient-provider relationships and improve respiratory care outcomes, as discussed at the European Respiratory Society (ERS) Congress.

The European Respiratory Society (ERS) Congress fosters collaboration among global experts, advancing respiratory health and promoting equality in medicine.

Social inequalities significantly impact COPD and PH outcomes, highlighting the need for systemic health care solutions, emphasizes Lucilla Piccari, MD, PhD, Hospital del Mar.

Cardiopulmonary risk is high and persistent across the entire COPD disease course, making early recognition and integrated care crucial.

Research reveals strong connections between muscle strength and cognitive function in patients with COPD, highlighting the potential for rehabilitation strategies.

Research exploring protective mechanical ventilation strategies for acute respiratory distress syndrome was presented at the ERS Congress by Luca Menga, MD, University of Toronto.

At the European Respiratory Society Congress, experts explored the critical connections between climate change, respiratory health, and health equity, highlighting the importance of integrated solutions, local action, and education.

Experts at the ERS Congress 2025 highlighted threats to scientific integrity from misinformation, political interference, and predatory publishing in health research.

Experts at European Respiratory Society (ERS) Congress 2025 highlight the critical link between reduced lung function and increased cardiovascular disease risk, urging early intervention and awareness.

Michaela Nuttal, MS, explores the complex culture of smoking among nurses, highlighting challenges and motivations for quitting within health care settings.

Nerandomilast for idiopathic pulmonary fibrosis potentially improves survival and slows disease progression, explains Justin Oldham, MD, PhD, MS, FIBRONEER steering committee member.